ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) traded up 3% during trading on Wednesday . The stock traded as high as $15.17 and last traded at $15.17. 8,071 shares changed hands during trading, a decline of 93% from the average session volume of 110,175 shares. The stock had previously closed at $14.73.
Analyst Ratings Changes
Separately, Morgan Stanley raised their target price on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an "equal weight" rating in a research note on Thursday, April 11th.
Read Our Latest Stock Analysis on ABIVAX Société Anonyme
ABIVAX Société Anonyme Price Performance
The stock has a fifty day simple moving average of $13.97.
Hedge Funds Weigh In On ABIVAX Société Anonyme
A number of hedge funds and other institutional investors have recently modified their holdings of ABVX. Blackstone Inc. purchased a new position in shares of ABIVAX Société Anonyme in the 4th quarter worth about $25,345,000. Commodore Capital LP purchased a new position in shares of ABIVAX Société Anonyme in the 4th quarter worth about $20,277,000. Great Point Partners LLC purchased a new position in shares of ABIVAX Société Anonyme in the 4th quarter worth about $16,585,000. Franklin Resources Inc. bought a new stake in shares of ABIVAX Société Anonyme in the 4th quarter valued at about $13,630,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of ABIVAX Société Anonyme in the 4th quarter valued at about $10,807,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.
ABIVAX Société Anonyme Company Profile
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Featured Articles
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
